Evidence map›Paper›PMID 42828121›Full record

ArticleInternational journal of pharmaceutics: X2026

Reprogramming macrophage polarization via CD44-targeted and ROS-responsive apabetalone-loaded micelles for rheumatoid arthritis treatment.

Jing-Feng Huang, Wen Qin, Dong-Mei Xiao, Hai-Bo Mao, Guo-Hua Fu, Jing-Bo Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jing-Feng HuangDepartment of Radiology, The First Affiliated Hospital of Ningbo University, Ningbo 315010, Zhejiang, People's Republic of China.
Wen QinDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Ningbo University, Ningbo 315010, Zhejiang, People's Republic of China.
Dong-Mei XiaoDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Ningbo University, Ningbo 315010, Zhejiang, People's Republic of China.
Hai-Bo MaoFaculty of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, People's Republic of China.
Guo-Hua FuArrhythmia Center, The First Affiliated Hospital of Ningbo University, Ningbo 315010, Zhejiang, People's Republic of China.
Jing-Bo HuFaculty of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current treatments for rheumatoid arthritis (RA) are highly limited by poor joint targeting, systemic toxicity, and an inability to precisely modulate the complex inflammatory microenvironment driven by overactive macrophages and elevated reactive oxygen species (ROS). To address these core challenges, this study developed a novel dual-functional nanoplatform: chondroitin sulfate-thioketal-poly(lactic-

Indexed as

Chondroitin sulfateMacrophage polarizationRheumatoid arthritisROS-responsive releaseTargeted drug delivery

Identifiers

PMID42828121
PMCPMC13631667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.